Digestive enzymes refer to compounds that aid in digestion by assisting with food breakdown. These proteins accelerate the chemical processes that transform food into compounds that can be absorbed by the digestive system. The salivary glands and the cells lining the stomach, pancreas, and small intestine produce (release) them. The main types of digestive enzymes are carbohydrates, protease, lipase, and other enzyme types. Lipase is a protein produced by the pancreas; a small organ located near the stomach that aids in fat digestion. The enzymes originated from animals, fungi, microbial, and plants that are used for indigestion, chronic pancreatitis, irritable bowel syndrome, and other applications. The various distribution channel includes retail stores and online stores. The digestive enzymes market research report is one of a series of new reports from The Business Research Company that provides digestive enzymes market statistics, including digestive enzymes industry global market size, regional shares, competitors with a digestive enzymes market share, detailed digestive enzymes market segments, market trends and opportunities, and any further data you may need to thrive in the digestive enzymes industry. This digestive enzymes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global digestive enzymes market grew from $0.82 billion in 2022 to $0.89 billion in 2023 at a compound annual growth rate (CAGR) of 9.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digestive enzymes market is expected to grow from $1.32 billion in 2027 at a CAGR of 10.3%. The rising prevalence of the gastrointestinal disorder among different age groups drives the growth of the digestive enzymes market. Gastrointestinal disorders include disorders in the gastrointestinal tract starting from the mouth, oesophagus, stomach, small intestine, large intestine, and anus caused due to lack of digestive enzymes. Gastrointestinal disorders require the digestive enzymes to be taken orally as a dietary supplement or as a drug. The increased rates of gastrointestinal disorders are linked to smoking, diet and genetics, sanitation, increased use of antibiotics, and the changing environmental factors due to industrialization and urbanization. According to the American Gastroenterological Association’s survey published in April 2020 on the worldwide prevalence and burden of functional gastrointestinal disorders, among 73,076 adult respondents, about 40.3% of people met the diagnostic criteria for at least 1 functional gastrointestinal disorder (FGIDs). FGID was more prevalent among women than men. A large-scale multinational study found that more than 40% of the population is having FGIDs across the globe. Therefore, the increase in the prevalence of digestive diseases contributes to the growth of the market. The potential side effects of digestive enzyme supplements and drugs restrain the growth of the digestive enzymes market. Continuous intake of digestive enzymes increases dependency on the digestive enzymes resulting in a weaker digestive system over time. The weakened digestive system leads to digestive distress, gas, nausea, bloating, decreased stomach acid, and allergic reactions accompanied by diarrhea and vomiting. For instance, the digestive enzyme bromelain causes thinning of the blood and increases the risk of excess bleeding. The thinning of the blood is the result of the anti-platelet activity caused by the drug. Thus, the side effects caused by the excess and continuous intake of digestive enzymes negatively impact the growth of the digestive enzyme market. The companies in the digestive enzymes market are investing in developing customized digestive enzymes. These customized digestive enzymes are condition-specific enzymes to support digestion for digestive sensitive patients and may contain multiple enzymes in the same product. The companies involved in manufacturing digestive enzymes are developing customized digestive enzymes to ease the digestion of different types of food. For instance, Sabinsa, a USA-based provider of herbal extracts, cosmeceuticals, minerals, and dietary supplements, formulated DigeZyme. DigeZyme is a multi-enzyme complex comprising five different enzymes, namely, cellulase, lactase, amylase, lipase, and protease. It is widely used by people who have difficulty in digesting carbohydrates, fats, and proteins, respectively. The companies are increasingly investing in developing customized digestive enzymes. In January 2020, Nestlé, a Switzerland-based food and drink processing corporation, entered into an asset purchase agreement with Allergan, an Ireland-based pharmaceutical company that acquires, develops, and markets brand name drugs, to acquire Zenpep for an amount undisclosed. Through the acquisition, Nestle aims to expand its medical nutrition portfolio by including Zenpep products to support food ingestion, digestion, and absorption. Zenpep is a medication for people who cannot digest food properly due to the lack of digestive enzymes. Major players in the digestive enzymes market are Garden of Life, Biotics Research Corporation, Klaire Laboratories, Abbott Nutrition, AbbVie Inc., Allergan PLC., Johnson & Johnson Inc. Amway Corporation, Food State Inc., Matsun Nutrition, Metagenics Inc., Twinlab Corporation, Food State Inc., AST Enzymes, VEMO 99 OOD, Advanced Vital Enzymes Pvt. Ltd., Zeus Biotech Limited, Vox Nutrition Inc., Enzyme Bioscience Pvt. Ltd., Metagenics, XYMOGEN Inc., Douglas Laboratories, Thorne Research, Integrative Therapeutics LLC., Pure Encapsulations, Ortho Molecular Products Inc., Designs for Health Inc., Master Supplements Inc., and Proteozymes. North America was the largest region in the digestive enzymes market in 2022. Middle East is expected to be the largest growing region in the global digestive enzymes market during the forecast period. The regions covered in the global digestive enzymes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive enzymes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The digestive enzymes market consists of sales of amylase, maltase, and lactase. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive enzymes market is segmented - 1) By Enzyme Type: Carbohydrates, Protease, Lipase, Other Enzyme Types 2) By Origin: Animal, Fungi, Microbial, Plant 3) By Application: Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications 4) By Distribution Channel: Retail Stores, Online Stores

Smart pills are used to deliver medication and are equipped with electronic sensors that emit signals to be captured by patches or smartphones when they are swallowed. These pills ensure drug regimen compliance and help track medication adherence of patients. The main applications of smart pills are capsule endoscopy, patient monitoring, and drug delivery, patient monitoring involves the repeated or continuous observations or measurements of the patient parameters. These pills are used to target the esophagus, stomach, small intestine, and large intestine to treat diseases such as esophageal diseases, colon diseases, small bowel diseases, and others. Smart pills are used by various end-users such as hospitals, diagnostic centres, and research institutes. The smart pills market research report is one of a series of new reports from The Business Research Company that provides smart pills market statistics, including smart pills industry global market size, regional shares, competitors with a smart pills market share, detailed smart pills market segments, market trends and opportunities, and any further data you may need to thrive in the smart pills industry. This smart pills market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global smart pills market size will grow from $4.48 billion in 2022 to $4.98 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global smart pills market size is expected to grow to $7.61 billion in 2027 at a CAGR of 11.2%. The growing preference for non-invasive procedures is driving the smart pills market. The non-invasive procedures are diagnostic and treatment procedures that do not require an incision on the body or removal of tissues for the treatment or diagnosis. Smart pill is a wireless, ingestible capsule that can be easily swallowed and has a wide range of applications in capsule endoscopy, drug delivery, and patient monitoring. For instance, smart pills have key applications in diagnostic imaging such as capsule endoscopy. The capsule endoscopy is a diagnostic procedure in which a smart pill (capsule enclosed micro-camera) is swallowed and images of the esophagus, stomach, and small intestine can be taken as the device pass through your gastrointestinal (GI) tract. Smart pills have revolutionized the diagnosis of gastrointestinal disorders and could replace conventional diagnostic techniques such as endoscopy. Therefore, non-invasive procedures are driving the smart pills market during the period. The high cost of smart pills associated with technological advancement will act as a restraint to the market growth. The utilization of advanced technologies including software up-gradation and innovative systems, and the integration of microchips contribute to the high manufacturing costs of the smart pills. Smart pills are a combination of drug and device technology. A smart pill is an innovative method of drug delivery, which involves the use of sensors and cameras embedded into tiny edible devices. Such medical devices ensure better diagnostics, monitoring, and treatment of life-threatening medical conditions by allowing doctors to monitor their patients’ body functions in real-time. However, the high cost of smart pills led to the limited utilization of products in underdeveloped countries. Thus, the high cost is considered as one of the factors that restrain the growth of the small pills market. Extensive research and development are being carried out on the use of miniature chips such as Addressable Transmitters Operated as Magnetic Spins (ATOMS) which can be used as smart pills. ATOMS are silicon chip devices that use the principle of magnetic resonance imaging (MRI) to determine the location of atoms in a patient’s body using magnetic fields. ATOMS can be used in ingestible smart pills to diagnose and treat diseases from within the body. The devices can be used to monitor a patient’s gastrointestinal tract, blood, or brain. They also could measure factors that indicate the health of a patient such as pH, temperature, pressure, and sugar concentrations, and relay that information to doctors. The devices could even be instructed to release drugs. For instance, scientists at Caltech (California Institute of Technology) have developed a miniature medical chip that can be used as a smart pill. Major players in the smart pills market are Medtronic PLC., Olympus Medical Technology, CapsoVision, Inc., Novartis AG, Proteus Pharmaceuticals, Philips Healthcare, Microchips, Bio-Images Drug Delivery (BDD) Limited, Given Imaging, Inc., and Vitality. North America was the largest region in the smart pills market in 2022. Western Europe was the second-largest region in the global smart pills market. The regions covered in the global smart pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the smart pills market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The smart pills market consists of sales of instruments that are used in applications such as capsule endoscopy, drug delivery, and patient monitoring. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global smart pills market is segmented - 1) By Application: Capsule Endoscopy, Patient Monitoring, Drug Delivery 2) By End User: Hospital, Diagnostic Center, Research Institute 3) By Target Area: Esophagus, Stomach, Small Intestine, Large Intestine 4) By Disease Indication: Esophageal Diseases, Colon Diseases, Small bowel Diseases, and Other Disease Indications

Microbiome refers to a group of microbes that live in a certain habitat and include fungi, bacteria, and viruses. It is all of the bacteria, fungi, protozoa, and viruses' genetic material that dwells on and within the human body. The microbiome's bacteria also aid in digestion, immune system control, defence against disease-causing bacteria, and the production of vitamins like Vitamin K, which is required for blood clotting, and the B vitamins B12, thiamine, and riboflavin. The main types of microbiomes are faecal microbiota transplantation (FMT) and microbiome drugs. The technique of transferring faecal bacteria and other germs from one healthy person to another is known as faecal microbiota transplantation or stool transplantation. The different technologies include genomics, proteomics, and metabolomics and are used in inflammatory bowel disease, diabetes, multiple sclerosis, rheumatoid arthritis, and others. The microbiome market research report is one of a series of new reports from The Business Research Company that provides microbiome market statistics, including microbiome industry global market size, regional shares, competitors with a microbiome market share, detailed microbiome market segments, market trends, and opportunities, and any further data you may need to thrive in the microbiome industry. This microbiome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global microbiome market size will grow from $0.39 billion in 2022 to $0.57 billion in 2023 at a compound annual growth rate (CAGR) of 45.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiome market size is expected to grow from $1.09 billion in 2027 at a CAGR of 17.6%. The increasing prevalence of inflammatory bowel disease (IBD) is a key factor driving the growth of the microbiome market. Inflammatory bowel disease (IBD) is a multifactorial and autoimmune infection group consisting of two major entities such as ulcerative colitis (UC) and Crohn's disease (CD). Fecal microbiota transplantation (FMT) and probiotics were discovered as having potential applications in many immune-mediated disorders, such as IBD, to restore microbial balance. These microbial therapies have shown the potential to reduce both the dysbiotic condition and the development of inflammatory mediators, thereby enabling remission, particularly in UC. For instance, in September 2020, according to the National Institute of Health, a US-based biomedical and public health research agency, between 600,000 and 900,000 Americans may suffer from ulcerative colitis. Therefore, the increasing prevalence of inflammatory bowel disease (IBD) is expected to drive the growth of the microbiome market. The high cost of microbial therapy is a key factor hampering the growth of the microbiome market. The price of fecal transplantation, a microbial therapy, may vary considerably depending on the delivery method used by users and where users receive it. Fecal microbiota transplant processes can charge around $600-$1,000 based on the method of treatment, area, insurance coverage, and other variables. Therefore, the high cost of microbial therapy is expected to hinder the growth of the microbiome market. The growing technological improvement is a major trend gaining popularity in the microbiome market. Major companies in the microbiome sector are focusing on developing advanced technology solutions for microbiomes. For instance, Seed, a new microbiome company, has introduced Probiotic and Prebiotic Daily Synbiotic for both females and males. The Daily Synbiotic Seed is the first to follow a microbe-system strategy with strain-specific advantages beyond digestive health such as cardiac safety, dermatological health, immune control, reproductive health, the integrity of the gut barrier, and oxidative stress. In January 2021, Novozymes, a Denmark-based biotechnology company, acquired Microbiome Labs for an undisclosed amount. Microbiome Labs’ acquisition is a crucial step in expanding Novozymes’ Human Health platform, giving it exposure to a wide range of patented solutions as well as access to the firm’s network of health professionals. Microbiome Labs is a probiotics company based in the United States. Major players in the microbiome market are MicroBiome Therapeutics LLC., Seres Therapeutics, Enterome Bioscience, Second Genome, Vedanta Biosciences Inc., AbbVie Inc., Rebiotix, Inc., Ritter Pharmaceuticals, LNC Therapeutics Inc., and ViThera Pharmaceuticals Inc. North America was the largest region in the microbiome market in 2022. The regions covered in the global microbiome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the microbiome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The microbiome market consists of sales of firmicutes, bacteroidetes, and actinobacteria. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global microbiome market is segmented - 1) By Type: Fecal Microbiota Transplantation (FMT), Microbiome Drugs 2) By Application: Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, Other Applications 3) By Technology: Genomics, Proteomics, and Metabolomics

Biosimilar interleukins is defined as a biosimilar produced by the body's leukocytes (white blood cells). Immune reactions are controlled by interleukins. Laboratory-produced interleukins are used as biological response modifiers to strengthen the immune system in cancer treatment. The different types of biosimilar interleukins are IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and others, and are distributed through various channels such as hospital pharmacies, online pharmacies, retail pharmacies, clinics, and research institutes. The biosimilar interleukins market research report is one of a series of new reports from The Business Research Company that provides biosimilar interleukins market statistics, including biosimilar interleukins industry global market size, regional shares, competitors with a biosimilar interleukins market share, detailed biosimilar interleukins market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar interleukins industry. This biosimilar interleukins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar interleukins market grew from $2.01 billion in 2022 to $2.8 billion in 2023 at a compound annual growth rate (CAGR) of 39.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar interleukins market is expected to grow from $10.54 billion in 2027 at a CAGR of 39.3%. The increasing prevalence of autoimmune diseases such as psoriasis and rheumatoid arthritis is expected to boost the growth of the interleukin biosimilars market in the forecast period. Autoimmune disorders are conditions in which the immune cells cannot distinguish healthy cells from potentially dangerous antibodies. Biologic drugs such as anti-interleukin antibodies have shown significant clinical benefits in regulating the cells, and in directing proliferation, activation, and migration of the cells. According to a Johns Hopkins University report published in 2021, autoimmune diseases affected approximately 3% of the population in the United States, or approximately 10 million people.Therefore, the increasing prevalence of autoimmune diseases is increasing the demand for the biosimilar interleukins market and is expected to drive the growth of the market. The regulatory framework around the approval of interleukin biosimilars hampers the growth of the market. Biosimilars are manufactured with changes in the manufacturing process that impact the physicochemical and functional properties of a biological drug, and it is impractical to create an exact copy of the biological drug. This compels the manufacturers to demonstrate biosimilarity between interleukin biosimilar and the biologic drug to prove that there are no clinically meaningful differences. This calls for extensive comparative analytical, nonclinical, and clinical assessments to get approval from the medical authorities, thereby, increasing the cost of the approval process and restraining the growth of the market. In January 2020, Sanofi, a France-based pharmaceutical company, acquired Synthorx, Inc. for $2.5 billion. This acquisition enhances Sanofi’s position as an emerging leader in the areas of oncology and immunology. Synthorx, Inc. is a US-based biotechnology company focused on developing interleukins for people suffering from cancer and autoimmune disorders. Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical. North America was the largest region in the biosimilar interleukins market in 2022. The regions covered in the global biosimilar interleukins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biosimilar interleukins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The biosimilar interleukins market consists of sales of mabPharm, gedeon richter, and bio-thera solutions. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar interleukins market is segmented - 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applications 3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes

Interleukin inhibitors refer to a substance used to suppress the immune system that prevents interleukins from working. Interleukins are a class of cytokines produced by white blood cells in response to infection (lymphocytes, monocytes, and macrophages). They are crucial to the control of the immune system. The main types of interleukin inhibitors are IL-17, IL-23, IL-1, IL-5, IL-6, and others. Interleukin 17 is a pro-inflammatory cystine knot cytokine family. In response to IL-23 stimulation, they are produced by a subset of T helper cells known as T helper 17 cells. The different applications include psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. The interleukin inhibitors market research report is one of a series of new reports from The Business Research Company that provides interleukin inhibitors market statistics, including interleukin inhibitors industry global market size, regional shares, competitors with an interleukin inhibitors market share, detailed interleukin inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the interleukin inhibitors industry. This interleukin inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global interleukin inhibitors market grew from $31.73 billion in 2022 to $36.96 billion in 2023 at a compound annual growth rate (CAGR) of 16.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The interleukin inhibitors market is expected to grow from $68.56 billion in 2027 at a CAGR of 16.7%. An increase in the number of investigational drugs for inflammatory diseases such as psoriasis, arthritis, and inflammatory bowel disease will drive the interleukin inhibitor market. Inhibitors of interleukin decrease the actions of the inflammatory cytokines, stimulate innate immune responses to prevent damage to the host, and maintain normal tissue homeostasis. There are 48 molecules under investigation for the treatment of inflammatory diseases such as psoriasis and psoriatic arthritis. Among these, 20 molecules are in Phase III clinical trials. These growing numbers of pipeline drugs will drive the interleukin inhibitor market upon approval. High costs associated with biological therapy are hampering the interleukin inhibitor market. The biologic treatment that has revolutionised the care of psoriasis patients is more expensive than the other treatments. The total annual cost ranged from $2,077 to $13,132 in the US for psoriasis and from $10,924 to $17,050 for psoriatic arthritis, per patient. As of 2020, biologics treatment costs were around $10,000 to $30,000 per year. The higher price of biologics and low healthcare expenditure in developing countries are therefore likely to hinder market growth. The patent expiration of biologic drugs creates opportunities for biosimilar drugs, which are a less expensive alternative.Major companies in the interleukin sector are focusing on developing biosimilars for interleukin inhibitors. For instance, biosimilars for IL inhibitors such as canakinumab (Ilaris), ustekinumab (Stelara), tocilizumab (Actemra), and secukinumab (Cosentyx), among others, are in development by Mabpharm, NeuClone Pharmaceuticals Ltd., Gedeon Richter, and Bio-Thera Solutions, respectively. Despite the clinical benefits associated with the use of biologics in psoriasis and other autoimmune diseases, many patients are not treated with biological therapy, and access to treatment may be limited for several reasons, including higher treatment costs. This factor, coupled with rapid advances in biotechnology and analytical sciences that ensure comparability of biosimilars to biological drugs, drives the trend for biosimilars. Major players in the interleukin inhibitors market are Sanofi, GlaxoSmithKline, Novartis, Johnson & Johnson, Roche, Eli Lilly, AstraZeneca, Teva Pharmaceutical, and Regeneron Pharmaceuticals. North America was the largest region in the interleukin inhibitors market in 2022. The regions covered in the global interleukin inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interleukin inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The interleukin inhibitors market consists of sales of anakinra, canakinumab, and rilonacept. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global interleukin inhibitors market is segmented - 1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Other Types 2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

C-reactive protein testing measures the level of c-reactive protein (CRP) in the blood. CRP is a liver-produced protein released into the bloodstream due to inflammation. When the body is wounded or infected, inflammation is the body's way of protecting the tissues. CRP testing is generally used to diagnose inflammation caused due to an infection. The main types of assays in c-reactive protein testing market are enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA) and immunoturbidimetric assays. The enzyme-linked immunosorbent assay (ELISA) is used to measure CRP (c-reactive protein). C-reactive protein (CRP) ELISA test offers quantitative measurement of human c-reactive protein in serum to help in the follow-up of rheumatic fever, inflammatory processes, and others. Elisa is a biological assay that measures antibodies, antigens, proteins, and glycoproteins. The c-reactive protein testing is mainly used in clinics, hospitals and diagnostic laboratories for diseases such as diabetes, rheumatoid arthritis, cardiovascular disease, inflammatory bowel disease, cancer and others. The c-reactive protein testing market research report is one of a series of new reports from The Business Research Company that provides c-reactive protein testing market statistics, including c-reactive protein testing industry global market size, regional shares, competitors with an c-reactive protein testing market share, detailed c-reactive protein testing market segments, market trends and opportunities, and any further data you may need to thrive in the c-reactive protein testing industry. This c-reactive protein testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global c-reactive protein testing market size grew from $3.28 billion in 2022 to $3.37 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The c-reactive protein testing market size is expected to grow to $3.67 billion in 2027 at a CAGR of 2.2%. The increase in cases of cardiovascular diseases (CVD) are expected to propel the growth of the c-reactive protein testing market. Cardiovascular diseases refer to heart conditions such as diseased vessels, structural problems, and blood clots. The exact cause of CVD is uncertain, but numerous factors can increase the risk of developing it. One such factor is the behavioral risk caused due to unbalanced eating, lack of physical activity, smoking, and alcohol use, which results in an accumulation of fatty deposits inside the arteries (atherosclerosis), resulting in an increased risk of blood clots. These behavioral risks result in elevated blood pressure, glucose, blood lipids, weight gain, and obesity. The increasing cases of cardiovascular diseases invites the need for c-reactive protein testing to diagnose or predict the chance of having cardiovascular problems at least as well as cholesterol levels. For instance, according to the key facts published in June 2021 by the WHO (World Health Organization), cardiovascular diseases are the leading cause of death worldwide. Around 17.9 million die every year due to CVD, accounting for 32% of all global deaths. Therefore, the increasing cases of cardiovascular diseases will drive the c-reactive protein testing market. Technological advancement in measuring devices is a key trend in the c-reactive protein testing market. Major companies operating in the c-reactive protein testing market are focused on providing technologically advanced solutions to strengthen their market position. These companies are implementing next-generation c-reactive testing technologies into their testing methods and advanced solutions that provide benefits such as maximum output and multiple usages. For instance, in February 2022, Aidian, a Finnish-based diagnostic tests, and test solutions company, released the QuikRead go wrCRP & wrCRP+Hb kits. The kit consistently produces two results, a wide range of CRP and Hb, from a single sample with one analysis. The wide-range CRP test permits CRP readings to assess conditions such as neonatal sepsis, predict disease severity in COPD (chronic obstructive pulmonary disease), and assist in cardiovascular risk assessment. In October 2021, Abcam, a UK-based producer, distributor, and marketer of protein research tools, acquired BioVision Inc., for $340 million. This acquisition is expected to increase Abcam's immunoassay capacity in Eugene, OR, by expanding the kits and assay portfolio. In addition to accelerating strategy execution, the company will also focus on in-house innovation and product development in the complementary biochemical and cell-based assay markets. BioVision Inc. is a US-based innovator and distributor of life science research tools, including CRP ELISA kits, to biopharma, diagnostic, and academic customers. Major players in the c-reactive protein testing market are Thermo Fisher Scientific Inc., F Hoffmann-La Roche Ltd., Danaher, Quest Diagnostics, Siemens Healthineers, Abbott Laboratories, Laboratory Corporation of America Holdings, Merck, Abaxis Inc. (Zoetis), Ortho Clinical Diagnostics, Getein Biotech, Horiba, Randox Laboratories, Boditech Med, Eurolyser Diagnostica GmbH, Aidian, EKF Diagnostics, SD Biosensor Inc., Abcam plc, and Bio-Techne. North America was the largest region in the c-reactive protein testing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the c-reactive protein testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The c-reactive protein testing market includes revenues earned by entities by devices and reagents. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.  The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global c-reactive protein testing market is segmented - 1) By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays 2) By End Use: Clinics, Hospitals, Diagnostic Laboratories 3) By Application: Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer, Other Applications

Digestive health supplements refer to a nutritional supplement that aids in the breakdown of food and liquids into their chemical constituents—carbohydrates, lipids, proteins, and the like—so that the body may absorb them as nutrients and utilise them for energy, cell growth, and repair, and other functions.       The main products in the digestive health supplements market are prebiotics, probiotics, enzymes, fulvic acid, and other products. Prebiotics refer to a type of carbohydrate, mostly fibers, that humans cannot digest but are digestible by their gut bacteria. The main forms include capsules, tablets, powders, liquids, and other forms. They are sold through various distribution channels such as supermarkets or hypermarkets, convenience stores, specialty stores, pharmacies, e-commerce, and other distribution channels. The digestive health supplements market research report is one of a series of new reports from The Business Research Company that provides digestive health supplements market statistics, including digestive health supplements industry global market size, regional shares, competitors with a digestive health supplements market share, detailed digestive health supplements market segments, market trends and opportunities, and any further data you may need to thrive in the digestive health supplements industry. This digestive health supplements market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digestive health supplements market size grew from $14.02 billion in 2022 to $15.46 billion in 2023 at a compound annual growth rate (CAGR) of 10.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digestive health supplements market size is expected to grow to $22.69 billion in 2027 at a CAGR of 10.1%. The rising prevalence of digestive diseases is expected to propel the growth of the digestive health supplement market going forward. A digestive disease is any health problem that affects the digestive tract. These problems can range from mild to severe. Digestive health supplements like probiotics, prebiotics, and enzymes help with digestive problems like diarrhea, constipation, inflammatory bowel disease, irritable bowel disease, urinary tract infection, and other gastrointestinal-related digestive problems. For instance, according to the International Foundation for Gastrointestinal Disorders, irritable bowel syndrome is the most common functional GI disorder, with a prevalence rate of 10–15% globally. Additionally, it is one of the most common conditions that require a visit to the doctor. Thus, the rising prevalence of digestive diseases will increase sales and awareness of digestive health supplements, thereby, driving the growth of the digestive health supplement market. Product innovation is the key trend gaining popularity in the digestive health supplements market. Major companies operating in the market are introducing technological innovations such as new ingredients and exploring innovative administration forms to cater to the needs of various age groups to sustain their position in the market. For instance, in April 2021, Bausch Health Companies Inc., a US-based pharmaceutical company, launched a unique proprietary blend of five probiotic strains ingredients, ENVIVE, an over-the-counter probiotic supplement that is formulated to strengthen and protect the digestive system. In May 2022, Glanbia Nutritionals, an Ireland-based nutrition company, acquired Sterling Technology for an amount of $60 million. Through this acquisition, Glanbia Nutritionals aims to scale and strengthen its bioactive solutions portfolio to cater to the needs of its customers. Sterling Technology is a US-based bioactive solution manufacturing company, which offers product solutions in digestive health, Tegricel, a solution that uses NSAIDs to keep the digestive tract healthy. Major players in the digestive health supplements market are Amway Corp, Bayer AG, Pfizer Inc., NOW Foods, Alimentary Health Limited, Nestle, Nutricia, Lonza, Nature’s Bounty, Garden of Life, Zenwise, OLLY Public Benefit Corporation, BASF SE, Herbalife International, and GlaxoSmithKline PLC North America was the largest region in the digestive health supplements market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in digestive health supplements market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive health supplements market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The digestive health supplements market consists of sales of L-glutamine, Slippery elm, Ginger root, and vitamin D. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive health supplements market is segmented - 1) By Product: Prebiotics, Probiotics, Enzymes, Fulvic Acid, Other Product 2) By Form: Capsules, Tablets, Powders, Liquids, Other Form 3) By Distribution Channel: Supermarkets/Hypermarkets, Convenience Store, Specialty Store, Pharmacies, E-Commerce, Other Distribution Channels

Digestive health is a system that enables the body to efficiently digest food and absorb nutrients, maintaining overall health. Constipation, heartburn, bloating, indigestion, and other digestive issues are less common in those with sound digestion, as are more severe digestive illnesses. The main types of digestive health products are functional foods and beverages, vitamins and dietary supplements, and other products. The functional foods and beverages offer health benefits beyond their nutritional value. Functional food and beverages are products that have an added physiological benefit above and beyond their naturally occurring benefits. The various ingredient used in digestive health products are probiotics, prebiotics, digestive enzymes, and other ingredients. The digestive health products are distributed through supermarkets/hypermarkets, hospital pharmacies, online pharmacies, and other distribution channels. The digestive health market research report is one of a series of new reports from The Business Research Company that provides digestive health market statistics, including digestive health industry global market size, regional shares, competitors with a digestive health market share, detailed digestive health market segments, market trends and opportunities, and any further data you may need to thrive in the digestive health industry. This digestive health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digestive health market size grew from $49.3 billion in 2022 to $55.7 billion in 2023 at a compound annual growth rate (CAGR) of 13.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digestive health market size is expected to grow to $84.45 billion in 2027 at a CAGR of 11.0%. The rising geriatric population is driving the digestive health market. The geriatric population consists of adults 65 years of age and older. The digestive system may not function as swiftly or as efficiently as it once did as people age because numerous biological processes slow down with advancing years. The muscles in the digestive system become stiffer, softer, and less effective over time. Digestive health products aid the body in efficiently digesting food and absorbing nutrients, maintaining overall health. For instance, in June 2020, according to a study by the United Nations, the total number of people age 80 years and above is expected to increase from 143 million in 2019 to over 426 million in 2050. Therefore, the increasing geriatric population is expected to aid the growth of the compression therapy market. New product innovation is a key trend in the digestive health market. Detoxification is gaining popularity, which is being taken as an opportunity by major digestive health companies. A series of procedures known as detoxification is intended to treat acute intoxication and withdrawal. For instance, in August 2022, JP Holistic Nutrition, a UK-based online pet supplement store, launched Urban Retreat RESET. Urban Retreat Reset detox is a beverage for digestion and gut health. Digestive enzymes, probiotics, and prebiotics are all ingredients in this supplement for digestive health. It conatins alkalizing products that enhance wellbeing, sleep, mood regulation, and brain health. In March 2021, PanTheryx, the colostrum-based nutrition and biotechnology company, acquired TruBiotics from Bayer HealthCare LLC for an undisclosed amount. Through this acquisition, PanTheryx will expand its product portfolio in the probiotics and microbiome category. TruBiotics is a probiotic brand of Bayer AG, a German multinational pharmaceutical and biotechnology company, that specialises in nutritional supplements, including probiotics. Major players in the digestive health market are Chr. Hansen Holdings A/S, Yakult Honsha Co. Ltd., Nestle SA, DuPont, PepsiCo Inc., Danone A.S., Cargill Inc., General Mills, Inc., Arla Foods, Inc., Mondelez International Inc., Deerland Probiotics & Enzymes, Inc., Sanofi, BASF SE, Bayer AG and AST Enzymes. North America was the largest region in the digestive health market in 2022. The regions covered in the digestive health market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the digestive health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The digestive health market includes revenues earned by entities by food enzymes and microbial-based ingredients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digestive health market is segmented - 1) By Product Type: Functional Foods and Beverages, Vitamins and Dietary Supplements, Other Products 2) By Ingredient Type: Probiotics, Prebiotics, Digestive Enzymes, Other Ingredients 3) By Distribution Channel: Supermarkets/Hypermarkets, Hospital Pharmacies, Online Pharmacies, Other Distribution Channels